Atlas Trials

SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

Clinical trial NCT06516445 · UNKNOWN

Trial details

NCT number
NCT06516445
Sponsor
Huazhong University of Science and Technology
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Colorectal Cancer
Start date
2023-06-28
Primary completion
2025-06-28
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.